INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Study Details
Study Description
Brief Summary
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
INCB7839 is an inhibitor of the ADAM (A Disintegrin and Metalloprotease) 10 and 17 proteases. Neuronal activity regulates glioma growth through neuroligin-3 (NLGN3). ADAM 10 is the protease responsible for NLGN3 release into the tumor microenvironment and represents a promising therapeutic target.
Pre-clinical studies of INCB7839 in patient-derived pediatric high-grade gliomas (GBM and DIPG) revealed that INCB7839 inhibits pediatric high- grade glioma growth and improves overall survival. In vivo testing also demonstrated that INCB7839 penetrates brain tissue sufficient to achieve its pharmacodynamic effect of ADAM10 inhibition. Further pre-clinical studies in other animals revealed minimal toxicity, including non-adverse to mild increases in serum hepatobiliary enzymes, protein, calcium, cholesterol values, along with minimal decreases in RBC mass parameters; all parameters recovered.
INCB7839 has been evaluated in Phase I and Phase II clinical trials for previously treated solid tumors and breast cancer. Of the adverse events (AEs) noted, the majority were mild-to-moderate in severity, the most frequent being fatigue, nausea, anorexia, diarrhea, emesis, abdominal pain, anemia and constipation. The dose-limiting toxicity for monotherapy with INCB7839 in Phase I clinical trials was declared to be deep venous thrombosis (DVT). Out of 41 patients, there was a total of 9 thrombotic events including mild superficial thrombophlebitis (n=1), DVT (n=4), vena cava thrombosis with renal insufficiency in a patient with squamous cell cancer of the head and neck (n=1), atrial thrombosis in patient with breast cancer (n=1), and pulmonary embolism in patients with hormone-refractory prostate cancer (n=2). Overall, INCB7839 does exhibit a pro-coagulant effect in some adult patients, resulting in an increased incidence of DVT, whether used alone or in combination. The mechanism of this effect is unknown, and there is no clear relationship between the frequency of thrombosis and the dose administered.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dose-finding INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years). |
Drug: INCB7839
INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
|
Outcome Measures
Primary Outcome Measures
- To evaluate the incidence of INCB7839 treatment-emergent adverse events in children with recurrent/progressive High-Grade Gliomas. [Up to 30 days post treatment.]
Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0.
- Maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839. [Up to 30 days post treatment.]
To estimate the maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839 administered orally in children with recurrent/progressive high-grade glioma.
- To characterize the area under the plasma concentration versus time curve (AUC) of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma. [Up to 3 days after the first dose in Course 1.]
The area under the curve (AUC) will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.
- To characterize the maximum concentration [CMAX] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma. [Up to 3 days after the first dose in Course 1.]
The maximum concentration [CMAX] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.
- To characterize the apparent oral clearance [CL/F] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma. [Up to 3 days after the first dose in Course 1.]
The apparent oral clearance [CL/F] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.
- To characterize the time to reach CMAX [TMAX] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma. [Up to 3 days after the first dose in Course 1.]
The time to reach CMAX [TMAX] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.
Secondary Outcome Measures
- To make a preliminary assessment of progression-free survival in children with recurrent/progressive high-grade glioma. [Up to 2 years following last dose of INCB7839.]
The progression-free survival will be reported.
- To make a preliminary assessment of overall survival in children with recurrent/progressive high-grade glioma. [Up to 2 years following last dose of INCB7839.]
The overall survival will be reported.
- To make a preliminary assessment of duration of response in children with recurrent/progressive high-grade glioma. [Up to 2 years following last dose of INCB7839.]
The duration of response will be reported.
Other Outcome Measures
- ADAM10 inhibition of HER2 extracellular domain in serum. [Course 1 (up to 28 days after the first dose).]
HER2 extracellular domain in serum will be reported.
- To assess and monitor ADAM10 inhibition of neuroligin-3 (NLGN3) in cerebral spinal fluid. [Up to 30 days post treatment.]
Neuroligin-3 (NLGN3) in cerebral spinal fluid will be reported.
- To characterize the maximum concentration [CMAX] of INCB7839 in cerebrospinal fluid. [Up to 30 days post treatment.]
The maximum concentration [CMAX] will be calculated based on the CSF pharmacokinetic samples.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologic diagnosis Patients with recurrent/progressive high-grade gliomas, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR a 25% increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis utilizing the MRI sequence best demonstrating tumor, OR the appearance of a new/metastatic tumor lesion since diagnosis.
-
Eligible diagnoses include but are not limited to the following: diffuse intrinsic pontine glioma (DIPG), H3K27M-mutant diffuse midline glioma (DMG), glioblastoma multiforme, anaplastic astrocytoma and anaplastic oligodendroglioma. Spinal cord tumors are eligible with pathologic confirmation of the above.
-
Please note: patients with a radiographically typical DIPG at diagnosis, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
-
Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of pontine glioma WHO II-IV.
-
Patients with diffuse or multi-focal disease are eligible; patients with leptomeningeal spread are eligible.
-
Age Patient must be ≥ 3 but ≤21 years of age at the time of enrollment.
-
BSA Patients must have a BSA ≥ 0.70-2.50 m2 for dose 120 mg/m2/dose BID. Patients must have a BSA ≥ 0.55-2.80 m2 for dose 80 mg/m2/dose BID (Patients who have BSA 0.55-1.00 m2 will only receive 100 mg AM dose).
-
Ability to Swallow Patient must be able to swallow tablets whole.
-
Measurable disease Patient must have measurable disease in two dimensions on MRI to be eligible.
-
Prior Therapy Patients must have recovered from the acute treatment-related toxicities (defined as < grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment on this study.
Chemotherapy Patients must have received their last dose of known myelosuppressive anticancer therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea.
Investigational/ Biologic Agent
• Biologic or investigational agent (anti-neoplastic): Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 7 days prior to study enrollment.
o For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
• Monoclonal antibody treatment and agents with known prolonged half-lives: Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the agent ≥ 28 days prior to study enrollment.
• Immunotherapies: Patients who have received checkpoint inhibitors or other immunotherapies with a known potential for pseudoprogression and who have assumed tumor progression must be at least 3 months from prior immunotherapy AND have at least two MRI scans at least 4 weeks apart demonstrating further progression OR have a biopsy to confirm tumor progression OR have new site(s) of disease.
Radiation
Patients must have had their last fraction of:
-
Craniospinal irradiation, whole brain radiation, total body irradiation or radiation to ≥ 50% of pelvis or spine ≥ 42 days prior to enrollment.
-
Focal irradiation ≥ 14 days prior to enrollment.
-
Local palliative irradiation to site other than primary tumor progression site ≥ 14 days prior to enrollment
Stem Cell Transplant
Patient must be:
-
≥ 6 months since allogeneic stem cell transplant prior to enrollment with no evidence of active graft vs. host disease
-
≥ 3 months since autologous stem cell transplant prior to enrollment
-- Neurologic Status
-
Patients with neurological deficits should have deficits that are stable for a minimum of 7 days prior to enrollment.
-
Patients with seizure disorders may be enrolled if seizures are well controlled.
-
Performance Status Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within two weeks of enrollment must be ≥ 50.
-
Organ Function
Patients must have adequate organ and marrow function as defined below:
-
Absolute neutrophil count ≥ 1.0 x 109 cells/ L
-
Platelets >100 x 109 cells/ L (unsupported, defined as no platelet transfusion within 7 days)
-
Hemoglobin ≥ 8g/dl (may receive transfusions)
-
Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
-
ALT (SGPT) and AST (SGOT) < 3 x institutional upper limit of normal (ULN)
-
Albumin ≥ 2 g/dL
-
Serum creatinine based on age/gender as noted in institutional normal range. Patients that are not within institutional normal range but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m2 are eligible.
-
Corticosteroids Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 7 days prior to enrollment.
-
Growth Factors Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (e.g. filgrastim, sargramostim or erythropoietin). 14 days must have elapsed if patient received a long-acting formulation.
-
Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.
-
Informed Consent The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.
-
HIV Positive Patients
HIV-positive patients are eligible if the following criteria are met:
-
Stable on their antiretroviral agents
-
Have CD4 counts above 400/mm3
-
Undetectable viral loads, and
-
No need for prophylactic medications for an opportunistic infections
Exclusion Criteria:
- Pregnancy or Breast-feeding Pregnant women or nursing mothers are excluded from this study. Female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Pregnant or breast-feeding women are excluded from this study due to risks of fetal and teratogenic adverse events as seen in animal studies.
-
Concurrent Illness
-
Patients with any clinically significant unrelated systemic illness (e.g., serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient's ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
-
Patients with any other current malignancy.
-
Concomitant Medications
• Patients who are receiving any other anti-cancer, investigational or alternative (e.g. cannabinoids) drug therapy are ineligible.
-
Prisoners Prisoners will be excluded from this study.
-
Inability to participate Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures and study restrictions.
-
Allergy Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition.
-
Thrombosis Risk
-
Patients with a known coagulopathy or bleeding disorder (e.g., von Willebrands disease) are not eligible.
-
Patients with a history of non-central line related thrombosis or disorders that promote clotting (e.g., anti-thrombin III deficiency, Lupus anticoagulant) are not eligible.
-
Significant family history of thrombosis (i.e. deep venous thrombosis or pulmonary embolus) in a first-degree relatives (i.e., parents or siblings) are not eligible.
Family history must be documented to the best extent it is known.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Children's Hospital Los Angeles | Los Angeles | California | United States | 90026 |
| 2 | Lucile Packard Children Hospital Stanford University | Palo Alto | California | United States | 94304 |
| 3 | Children's Hospital Colorado | Aurora | Colorado | United States | 80045 |
| 4 | Children's National Medical Center | Washington | District of Columbia | United States | 20010 |
| 5 | Children's Healthcare of Atlanta | Atlanta | Georgia | United States | 30322 |
| 6 | Lurie Childrens Hospital-Chicago | Chicago | Illinois | United States | 60614 |
| 7 | National Cancer Institute Pediatric Oncology Branch | Bethesda | Maryland | United States | 20892 |
| 8 | Dana Farber Cancer Institute | Boston | Massachusetts | United States | 02215 |
| 9 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
| 10 | Cincinnati Children Hospital Medical Center | Cincinnati | Ohio | United States | 45229 |
| 11 | Children Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | United States | 15224 |
| 12 | St. Jude Children Research Hospital | Memphis | Tennessee | United States | 38105 |
| 13 | Baylor College of Medicine | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- Pediatric Brain Tumor Consortium
Investigators
- Study Chair: Michelle Monje, MD, Stanford University and Lucile Packard Children's Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PBTC-056